MTM Investment Management LLC Acquires 1,200 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

MTM Investment Management LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 9.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,168 shares of the company’s stock after buying an additional 1,200 shares during the quarter. MTM Investment Management LLC’s holdings in Elanco Animal Health were worth $172,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after buying an additional 65,303 shares in the last quarter. Atom Investors LP lifted its holdings in Elanco Animal Health by 310.3% during the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after buying an additional 261,559 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after buying an additional 209,734 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Elanco Animal Health by 19.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after buying an additional 646,522 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after buying an additional 45,795 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of a number of analyst reports. UBS Group initiated coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. Morgan Stanley cut their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.29.

Elanco Animal Health Price Performance

ELAN stock opened at $11.38 on Thursday. The stock has a 50-day moving average price of $11.97 and a two-hundred day moving average price of $13.17. The stock has a market cap of $5.63 billion, a PE ratio of 28.45, a price-to-earnings-growth ratio of 2.69 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 1 year low of $11.11 and a 1 year high of $18.80.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.